X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $345.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 04, 2023
Details:
The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2023
Details:
The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2023
Details:
XEN1101 is a differentiated Kv7 potassium channel opener which is being evaluated under phase 2 clinical trials for the treatment of major depressive disorder (MDD).
Lead Product(s): XEN1101
Therapeutic Area: Psychiatry/Psychology Product Name: XEN1101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
XEN1101 is a differentiated Kv7 potassium channel opener administered as an adjunctive treatment for adult patients with focal epilepsy,being developed for the treatment of epilepsy and major depressive disorder.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the DBP of XEN1101 compared to placebo.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
XEN1101, a KCNQ channel opener, has been studied in Phase 2b clinical trial in adult patients demonstrated compelling efficacy results, with a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency when compared to placebo.
Lead Product(s): XEN1101
Therapeutic Area: Psychiatry/Psychology Product Name: XEN1101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
XEN1101, a differentiated Kv7 potassium channel modulator – administered as adjunctive treatment in adult patients with focal epilepsy.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
